| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Virology |
| Manuscript Type |
Review |
| Article Title |
Therapeutic implications of SARS-CoV-2 dysregulation of the gut-brain-lung axis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Samuel D Johnson, Omalla A Olwenyi, Namita Bhyravbhatla, Michellie Thurman, Kabita Pandey, Elizabeth A Klug, Morgan Johnston, Shetty Ravi Dyavar, Arpan Acharya, Anthony T Podany, Courtney V Fletcher, Mahesh Mohan, Kamal Singh and Siddappa N Byrareddy |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Institutes of Health |
R01AI129745 |
| National Institutes of Health |
R21MH113455 |
| National Institutes of Health |
R01DA052845 |
| National Institutes of Health |
R01AI113883 |
|
| Corresponding Author |
Siddappa N Byrareddy, PhD, Associate Professor, Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, 42nd Street and Emile Street, Omaha, NE 68198, United States. sid.byrareddy@unmc.edu |
| Key Words |
SARS-CoV-2; Gut; Microbiome; Lungs; Brain; Therapeutics |
| Core Tip |
Severe acute respiratory syndrome coronavirus 2 has spread rapidly, infecting and killing millions worldwide. In addition to respiratory symptoms, coronavirus disease 19 (COVID-19) is associated with enterocyte infection leading to intestinal inflammation, gut barrier damage, and microbial dysbiosis exacerbating the systemic inflammatory response. Viral infiltration to the central nervous system from cranial nerve innervation of the lungs and gut can also cause neuroinflammation and degeneration, which further dysregulates gut and lungs. This review summarizes recent findings on COVID-19 pathogenesis in the gut-brain-lung axis and offers therapeutic interventions to improve clinical outcomes. |
| Publish Date |
2021-08-04 07:56 |
| Citation |
Johnson SD, Olwenyi OA, Bhyravbhatla N, Thurman M, Pandey K, Klug EA, Johnston M, Dyavar SR, Acharya A, Podany AT, Fletcher CV, Mohan M, Singh K, Byrareddy SN. Therapeutic implications of SARS-CoV-2 dysregulation of the gut-brain-lung axis. World J Gastroenterol 2021; 27(29): 4763-4783 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i29/4763.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i29.4763 |
